Compare Amphastar Pharmaceuticals Inc (AMPH) vs Southwest Airlines Co (LUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Southwest Airlines Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Southwest Airlines Co trades at $48.23 (market cap $23.67B). The key difference: Southwest Airlines Co is far larger — about 28.7× Amphastar Pharmaceuticals Inc's market cap, and Southwest Airlines Co pays a 1.49% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LUV | |
|---|---|---|
Market Cap | $826.08M | $23.67B |
Sector | Health | Industrials |
52-Week High | $30.81 | $54.80 |
52-Week Low | $16.87 | $29.06 |
Enterprise Value | $1.22B | $26.74B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Southwest Airlines (LUV) trades at $48.43, down 1.61% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported mixed Q1 2026 earnings, missing estimates, but maintains a positive outlook with Q2 2026 EPS expected at $0.52. Recent news highlights sector tailwinds from lower fuel costs and a partnership with AWS to accelerate AI capabilities by 2028.
LUV presents a balanced risk-reward profile with a consensus price target of $52.47, offering ~8% upside. Key opportunities include earnings growth potential and favorable industry dynamics, while risks involve Boeing 737 MAX incidents and volatile fuel prices. Analyst sentiment is mixed, with 42% buy ratings, reflecting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
